Development of Multinational Definitions of Minimal Clinically Important Improvement and Patient Acceptable Symptomatic State in Osteoarthritis

被引：91

作者：

Bellamy, Nicholas ^{[1
,2
]}

Hochberg, Marc ^{[3
]}

Tubach, Florence ^{[4
,5
]}

Martin-Mola, Emilio ^{[6
,7
]}

Awada, Hassane ^{[8
]}

Bombardier, Claire ^{[9
,10
]}

Hajjaj-Hassouni, Najia ^{[11
,12
,13
,14
]}

Logeart, Isabelle ^{[15
]}

Matucci-Cerinic, Marco ^{[16
]}

van de Laar, Mart ^{[17
,18
]}

van der Heijde, Desiree ^{[19
]}

Dougados, Maxime ^{[20
]}

机构：

[1] Univ Queensland, Sch Med, Brisbane, Qld, Australia

[2] Royal Brisbane & Womens Hosp, Herston, Qld, Australia

[3] Univ Maryland, Sch Med, Baltimore, MD 21201 USA

[4] Univ Paris Diderot, Sorbonne Paris Cite, INSERM, UMR S 1123,INSERM,CIC EC 1425,UMR S 1123, Paris, France

[5] Hop Bichat Claude Bernard, AP HP, F-75877 Paris, France

[6] Hosp Univ La Paz, Madrid, Spain

[7] Univ Autonoma Madrid, Madrid, Spain

[8] St Joseph Univ, Hotel Dieu France, Beirut, Lebanon

[9] Univ Toronto, Toronto Gen Res Inst, Inst Work & Hlth, Toronto, ON, Canada

[10] Mt Sinai Hosp, Toronto, ON M5G 1X5, Canada

[11] Mohammed Vth Souissi Univ, CNRST, Rabat, Morocco

[12] Lab Informat & Res Bone Dis LIRPOS URAC 30, Rabat, Morocco

[13] El Ayachi Hosp, Sale, Morocco

[14] Univ Hosp, Sale, Morocco

[15] Pfizer, Paris, France

[16] Univ Florence, Denothe Ctr, Florence, Italy

[17] Med Spectrum Twente, Arthrit Ctr Twente, Enschede, Netherlands

[18] Univ Twente, NL-7500 AE Enschede, Netherlands

[19] Leiden Univ, Med Ctr, Leiden, Netherlands

[20] Paris Descartes Univ, Cochin Hosp, AP HP, INSERM U1153,PRES Sorbonne Paris Cite, Paris, France

来源：

ARTHRITIS CARE & RESEARCH | 2015年 / 67卷 / 07期

关键词：

OF-RHEUMATOLOGY CRITERIA; ANKYLOSING-SPONDYLITIS; RESEARCH-SOCIETY; HAND OSTEOARTHRITIS; REPORTED OUTCOMES; HIP OSTEOARTHRITIS; RESPONSE CRITERIA; MEANINGFUL CHANGE; NORMATIVE VALUES; RELEVANT CHANGES;

D O I：

10.1002/acr.22538

中图分类号：

R5 [内科学];

学科分类号：

100201 [内科学];

摘要：

ObjectiveThe ability to interpret scores from patient-reported outcome measures at the individual patient level depends on the availability of valid, clinically meaningful benchmarks of response and state attainment. The goal was to develop multinational estimates for minimal clinically important improvement (MCII) and patient acceptable symptomatic state (PASS). MethodsA multinational sample of patients with osteoarthritis (OA) was evaluated before and 4 weeks after treatment with nonsteroidal antiinflammatory drugs. Patients completed either the Western Ontario and McMaster Osteoarthritis Index (WOMAC) numerical rating scale 3.1 (hip and knee OA) or the Australian/Canadian Index (AUSCAN) numerical rating scale 3.1 (hand OA) before and after treatment. Patients rated the clinical importance of their response to treatment and their satisfaction with the health state achieved, from which multinational MCII and PASS estimates were calculated for both the WOMAC and AUSCAN indices. ResultsA total of 609 patients from 7 countries participated in the study. MCII and PASS estimates varied slightly by instrument and subscale. Absolute (percentage) change for MCII ranged 6-9 (10% to 17%) for WOMAC and 4-9 (8% to 15%) for AUSCAN. PASS estimates ranged 39-48 for WOMAC and 38-45 for AUSCAN. Some between-country variation was observed in MCII and PASS. ConclusionPreliminary multinational estimates for MCII and PASS have been developed for several countries. Further research is required to evaluate the robustness, temporal consistency, and age- and sex-dependency of the preliminary estimates as well as their generalizability to other countries, languages, cultures, regions, and other condition-specific outcome measures.

引用

页码：972 / 980

页数：9